PDF(Pubmed)
Abstract：
OBJECTIVE: This study investigated the effect of administering tamsulosin before surgery on the successful insertion of a 12/14 French (F) ureteral access sheath (UAS) during the procedure, as well as the impact of preoperative and postoperative tamsulosin use on symptoms related to the ureteral stent.
METHODS: This study was a randomized, single-center, double-blinded, placebo-controlled trial involving 200 patients who underwent unilateral retrograde intrarenal surgery. Patients received either tamsulosin (0.4 mg) or placebo 1 week before surgery until stent removal. Patients were randomly assigned to one of four groups. Group 1 received tamsulosin throughout the study period. Group 2 received tamsulosin before surgery and placebo after surgery. Group 3 received placebo before surgery and tamsulosin after surgery. Group 4 received placebo before and after surgery. The USSQ (Ureteral Stent Symptom Questionnaire) was completed between postoperative days 7 and 14 immediately before stent removal.
RESULTS: A total of 160 patients were included in this analysis. Their mean age was 55.0±11.0 years, and 48 patients (30.0%) were female. In the group that received preoperative tamsulosin, the success rate of 12/14F UAS deployment was significantly higher than that of the preoperative placebo group (88.0 vs. 75.3%, p=0.038). Preoperative and postoperative tamsulosin did not significantly alleviate symptoms related to the ureteral stent.
CONCLUSIONS: Our results revealed that preoperative administration of tamsulosin improved the success of larger-sized UAS, whereas preoperative and postoperative tamsulosin use did not significantly alleviate symptoms related to ureteral stents.
METHODS: This study was a randomized, single-center, double-blinded, placebo-controlled trial involving 200 patients who underwent unilateral retrograde intrarenal surgery. Patients received either tamsulosin (0.4 mg) or placebo 1 week before surgery until stent removal. Patients were randomly assigned to one of four groups. Group 1 received tamsulosin throughout the study period. Group 2 received tamsulosin before surgery and placebo after surgery. Group 3 received placebo before surgery and tamsulosin after surgery. Group 4 received placebo before and after surgery. The USSQ (Ureteral Stent Symptom Questionnaire) was completed between postoperative days 7 and 14 immediately before stent removal.
RESULTS: A total of 160 patients were included in this analysis. Their mean age was 55.0±11.0 years, and 48 patients (30.0%) were female. In the group that received preoperative tamsulosin, the success rate of 12/14F UAS deployment was significantly higher than that of the preoperative placebo group (88.0 vs. 75.3%, p=0.038). Preoperative and postoperative tamsulosin did not significantly alleviate symptoms related to the ureteral stent.
CONCLUSIONS: Our results revealed that preoperative administration of tamsulosin improved the success of larger-sized UAS, whereas preoperative and postoperative tamsulosin use did not significantly alleviate symptoms related to ureteral stents.
摘要：
目的：本研究调查了手术前施用坦索罗辛对手术期间成功插入12/14French（F）输尿管通路鞘（UAS）的影响，以及术前和术后使用坦索罗辛对输尿管支架相关症状的影响。
方法：这项研究是一项随机的，单中心,双盲,纳入200例接受单侧逆行肾内手术的患者的安慰剂对照试验.患者在手术前1周接受坦索罗辛（0.4mg）或安慰剂，直到支架移除。患者被随机分配到四组中的一组。第1组在整个研究期间接受坦索罗辛。第2组手术前接受坦索罗辛，手术后接受安慰剂。第3组手术前接受安慰剂，手术后接受坦索罗辛。第4组手术前后接受安慰剂。USSQ(输尿管支架症状问卷)在术后第7天至第14天之间在支架移除之前立即完成。
结果：本分析共纳入160例患者。他们的平均年龄为55.0±11.0岁，48例（30.0％）为女性。在接受术前坦索罗辛的组中，12/14FUAS部署的成功率明显高于术前安慰剂组(88.0vs.75.3%,p=0.038)。术前和术后坦索罗辛没有明显缓解与输尿管支架相关的症状。
结论：我们的结果表明，术前服用坦索罗辛可以提高大型UAS的成功率，而术前和术后使用坦索罗辛并未显著缓解与输尿管支架相关的症状.
方法：这项研究是一项随机的，单中心,双盲,纳入200例接受单侧逆行肾内手术的患者的安慰剂对照试验.患者在手术前1周接受坦索罗辛（0.4mg）或安慰剂，直到支架移除。患者被随机分配到四组中的一组。第1组在整个研究期间接受坦索罗辛。第2组手术前接受坦索罗辛，手术后接受安慰剂。第3组手术前接受安慰剂，手术后接受坦索罗辛。第4组手术前后接受安慰剂。USSQ(输尿管支架症状问卷)在术后第7天至第14天之间在支架移除之前立即完成。
结果：本分析共纳入160例患者。他们的平均年龄为55.0±11.0岁，48例（30.0％）为女性。在接受术前坦索罗辛的组中，12/14FUAS部署的成功率明显高于术前安慰剂组(88.0vs.75.3%,p=0.038)。术前和术后坦索罗辛没有明显缓解与输尿管支架相关的症状。
结论：我们的结果表明，术前服用坦索罗辛可以提高大型UAS的成功率，而术前和术后使用坦索罗辛并未显著缓解与输尿管支架相关的症状.
